Lupin gets approval from USFDA for ulcer drug
Lupin has received an approval from USFDA to market a generic drug in the US to treat ulcer
Drug firm Lupin has received a nod from US Food and Drug Administration to market the generic version of AstraZeneca's Prilosec delayed-release capsules, to treat ulcer. Lupin’s drug Omeprazole delayed-release capsules will be introduced in the strength of 40 mg in the American market.
The drug is also used for healing of erosive esophagitis and pathological hypersecretory conditions.
The Mumbai-based company's Omeprazole delayed-release capsules are the generic equivalent of AstraZeneca's Prilosec delayed-release capsules, which are indicated for the treatment of duodenal ulcer, gastric ulcer and gastro esophageal reflux disease (GERD), as confirmed by PTI.
Drug firm Lupin has received a nod from US Food and Drug Administration to market the generic version of AstraZeneca's Prilosec delayed-release capsules, to treat ulcer. Lupin’s drug Omeprazole delayed-release capsules will be introduced in the strength of 40 mg in the American market.
The drug is also used for healing of erosive esophagitis and pathological hypersecretory conditions.
The Mumbai-based company's Omeprazole delayed-release capsules are the generic equivalent of AstraZeneca's Prilosec delayed-release capsules, which are indicated for the treatment of duodenal ulcer, gastric ulcer and gastro esophageal reflux disease (GERD), as confirmed by PTI.
Next Story